MADRID, January 31 (EUROPA PRESS) –
More than 80 percent of clinical trials in oncology registered in Spain are being promoted by the pharmaceutical industry, Farmaindustria said on Monday's feast on Monday, February 4, on the World Cancer Day.
Within this framework, "the pharmaceutical industry is fully committed to the research, development and availability of new and more accurate anticancer drugs, and has opened doorway for the last few years with immunotherapies and new gene therapies, and cell phones, which are the basis for new precision medicine."
"Newer achievements also imply the consolidation of a new age in cancer approach, which is considered to be considered as a set of very different pathologies according to their molecular and genetic profiles," they added.
So remember that cancer continues to focus on a great deal of effort in the research and development of the pharmaceutical industry. This shows that 42 of the new drugs are approved in Europe in 2018, a total of 11 (26%) of new drugs against various types of cancer, including the first two gene therapies that stand out against different rare variants. according to the latest data from the European Medicines Agency (EMA).
In the same vein, 84 out of 84 positive opinions on new drugs released by EMA last year, 23 (27%) respond to treatments against different types of cancer. These positive opinions of EMAs become, in the later procedure, in the decisions on the authority of the European Commission.
Approved anti-tumor agents containing the new active substance are directed to the treatment of various blood tumors, as well as lung, breast, prostate, bladder, ovarian, pertoneum, and melanoma and lymphoma variants.
EXPERTISE IN CLINICAL RESEARCH
The latest data available in June 2017 from the BEST Project of Excellence in Clinical Drug Research shows that cancer pathology attracts most of the efforts in clinical trials, to the extent that almost 50% of all clinical trials launched by the pharmaceutical industry last year were developed on an oncologic area.
This oncology effort also followed a growing trend. Thus, in the period from 2004 to 2009, 31% of clinical trials promoted by the pharmaceutical industry involved in BEST corresponded to oncology, a percentage which increased to 39.4% in the period 2010-2014. And finally at 49.6% in the period 2015-2018.
Cancer, as confirmed by the latest figures, is a growing challenge in modern society, and this is what the pharmaceutical industry is trying to do. "All of this information points to the important efforts of research and development of pharmaceutical companies based in Spain to detect and develop new medicines that allow us to maximally guarantee the huge challenge of addressing cancer problems," says CEO. Farmaindustria, Humberto Arnés.
In his opinion, although significant advances have been made over the last decades, "there is still a long way to go, the way all involved agents (administrations, industry, health professionals, researchers and patients) have to move forward together if we want to get the best results give new solutions to patients who do not yet have them. "